For oncologists frustrated with their inability to change the course of SCLC after platinum-exposure, ZEPZELCA is the energizing solution that arms treaters with a life-extending treatment option, due to its durable efficacy, tolerability, and ease of administration.

With current options insufficient to meet patients’ needs, Lurbinectedin’s novel MoA offers a promise for the future, so that reinvigorated oncologists are inspired to change the course of SCLC, helping their patients achieve more positive life moments.